Skip to main navigation Skip to search Skip to main content

24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease

Project: Research

Project Details

StatusFinished
Effective start/end date06/17/16 → 06/16/20

Funding

  • Lilly Research Laboratories: $674,675.15